Uzhhorod National University, Uzhhorod 88000, Ukraine.
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NASU, Kyiv 03022, Ukraine.
Exp Oncol. 2022 Dec;44(4):295-299. doi: 10.32471/exp-oncology.2312-8852.vol-44-no-4.19152.
Hormonal therapy is one of the main methods of comprehensive treatment of patients with locally advanced breast cancer (BC). Despite the intensive search for molecules associated with the aggressiveness of the tumor process, currently there are no reliable markers predicting response to neoadjuvant hormonal therapy (NHT).
To investigate the correlation between miR-125b-2, -155, -221, -320a expression in tumor tissue and HER2/neu status and response to tamoxifen treatment in BC patients.
Expression levels of miR-125b-2, -155, -221, and -320a were analyzed in biopsy samples of 50 BC patients using a real-time polymerase chain reaction.
We found that levels of miR-125b-2, -155, -221, and -320a were 1.72, 1.65, 1.85, and 2.89 times higher in BC biopsy samples expressing estrogen/progesterone receptors and HER2/neu compared with HER2/neu-negative luminal tumors. Patients with a luminal BC showing higher levels of miR-125b-2 and miR-320a expression before therapy demonstrated better response to NHT with tamoxifen. A strong correlation was calculated for miR-221 expression and response to NHT (r = 0.61).
The high levels of miR-125b-2, -155, -221, and -320a in tumor tissue are associated with the HER2/neu-positive status of luminal BC subtypes. Tumor samples of patients showing the low response to NHT with tamoxifen are characterized by lower expression of miR-125b-2 and -320a. Hence, miR-125b-2 and -320a could be considered as putative predictive biomarkers associated with tamoxifen sensitivity of hormone-dependent BC.
激素治疗是局部晚期乳腺癌（BC）综合治疗的主要方法之一。尽管人们一直在积极寻找与肿瘤侵袭性相关的分子，但目前尚无可靠的标志物可预测新辅助激素治疗（NHT）的反应。
研究肿瘤组织中 miR-125b-2、-155、-221、-320a 的表达与 HER2/neu 状态以及 BC 患者对他莫昔芬治疗反应的相关性。
采用实时聚合酶链反应分析 50 例 BC 患者活检样本中 miR-125b-2、-155、-221 和 -320a 的表达水平。
我们发现，与 HER2/neu 阴性 luminal 肿瘤相比，表达雌激素/孕激素受体和 HER2/neu 的 BC 活检样本中 miR-125b-2、-155、-221 和 -320a 的水平分别高出 1.72、1.65、1.85 和 2.89 倍。在治疗前，miR-125b-2 和 miR-320a 表达水平较高的 luminal BC 患者对 NHT 与他莫昔芬的反应更好。miR-221 表达与 NHT 反应之间存在很强的相关性（r=0.61）。
肿瘤组织中 miR-125b-2、-155、-221 和 -320a 的高水平与 luminal BC 亚型的 HER2/neu 阳性状态相关。对 NHT 与他莫昔芬反应不佳的患者肿瘤样本的 miR-125b-2 和 -320a 表达水平较低。因此，miR-125b-2 和 -320a 可被视为与激素依赖性 BC 他莫昔芬敏感性相关的潜在预测生物标志物。
